Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coverage Study: Effect of Voxelotor on Cerebral Perfusion and Oxygenation in Sickle Cell Disease
2019-003766-41Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of voxelotor in sickle cell disease (SCD), sponsored by Amsterdam University Medical Center. Primary endpoint: Cerebral vascular reserve capacity (CVR). Started Jul 2020; status: active.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2019-003766-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003766-41.